CD4+ T helper 2 cells force breast cancer cells to revert to benign breast gland cells.
- Access to fat is more limited in brain tissue than in other tissues in the body, and breast cancer cells that spread to the brain must increase their production of fatty acids, the building blocks of fat.
- In mice, blocking such cells’ ability to synthesize fatty acids reduced breast tumor growth in the brain.
- The findings may be helpful for designing new treatments for patients whose cancer has spread to the brain.
Rakesh K. Jain, PhD
“To date, targeted therapies mostly focus on genetic vulnerabilities of cancer cells. Our work demonstrates that the environment in which the cancer cells reside can also dictate metabolic vulnerabilities that should be considered during the development of treatment strategies.”
Director, E.L. Steele Laboratories for Tumor Biology, Massachusetts General Hopsital
Therapies that target the human epidermal growth factor receptor 2 (HER2) have transformed treatment for patients with breast cancer whose tumor cells express HER2, but brain metastases from this disease are typically fatal because they are resistant to anti-cancer therapies that are effective in other locations in the body. This is in part due to the blood-brain barrier that protects the brain against circulating toxins and pathogens, but changes in the cancer cells once they reach the brain may also play a role.
Such changes may occur because cancer cells that metastasize to the brain encounter differences in nutrient availability in brain tissue relative to other tissues in the body. Therefore, the malignant cells may have to alter how and what they metabolize to support tumor survival and growth. To investigate this possibility, researchers designed experiments in mice that assessed how metabolism differs between breast tumors that traveled to the brain and other locations in the body.
The team found that access to fats is limited for breast tumors to grow in the brain. In response, fatty acid synthesis is elevated in these tumor cells, as a result of increased activity of an enzyme called fatty acid synthase. “Consistent with our preclinical findings, clinical specimens of brain metastases from patients over-express fatty acid synthase relative to tumors that have not metastasized,” says co–lead author Gino Ferraro, PhD, a postdoctoral fellow in the E.L. Steele Laboratories for Tumor Biology at MGH.
The findings demonstrate that when a cancer has spread to a particular organ, potential treatment strategies could take advantage of the nutrient availability at that site. Inhibiting the cancer cells’ ability to use that nutrient may lead to their demise.
“To date, targeted therapies mostly focus on genetic vulnerabilities of cancer cells. Our work demonstrates that the environment in which the cancer cells reside can also dictate metabolic vulnerabilities that should be considered during the development of treatment strategies,” says co–corresponding author Rakesh K. Jain, PhD, director of the E.L. Steele Laboratories for Tumor Biology at MGH and the Andrew Werk Cook Professor of Radiation Oncology at Harvard Medical School.
The team notes that an inhibitor of fatty acid synthase, called TVB2166, is currently being evaluated in patients with metastatic breast cancer. “This compound is not brain-permeable, however, and patients with symptomatic brain metastases are excluded from these trials,” says co–corresponding author Matthew Vander Heiden, MD, PhD, an associate director of the Koch Institute at MIT and a member of the Broad Institute of MIT and Harvard. “Therefore, the efficacy and safety of this strategy in patients with brain metastases remains to be explored using brain-penetrable fatty acid synthase inhibitors.”
This work was supported in part by a Koch Institute/DFHCC Bridge project grant, Susan G. Komen for the Cure, HHMI, National Science Foundation, Ludwig Center for Molecular Oncology Fund, Novo Nordisk Foundation, Knut and Alice Wallenberg Foundation, NIH, National Foundation for Cancer Research, the Ludwig Center at Harvard, Jane’s Trust Foundation, Advanced Medical Research Foundation, U.S. Department of Defense Breast Cancer Research Program Innovator Award, Stand Up to Cancer, the MIT Center for Precision Cancer Medicine, the Ludwig Center at MIT and the Emerald Foundation.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2020, Mass General was named #6 in the U.S. News & World Report list of "America’s Best Hospitals."
Related News and Articles
- Press Release
- Mar | 17 | 2022
Scientists discover that certain proteins surrounding organs and tissues switch off natural killer cells’ “killer” function. Blocking these interactions could re-activate the cells.
- Press Release
- Jan | 31 | 2022
In animal models, researchers develop a safe and effective strategy to treat glioblastoma, one of the most deadly and treatment-resistant cancers.
- Press Release
- Jan | 20 | 2022
Newly discovered DNA repair mechanisms point to potential therapy targets for cancer and neurodegenerative diseases
Investigators have identified nine new factors involved in the process of DNA repair that is critical to the health of human cells.
- Press Release
- Jan | 3 | 2022
A huge unmet need exists for therapeutic targets to prevent or delay metastasis of breast cancer to the brain, the leading cause of death from the malignancy.
- Press Release
- Dec | 6 | 2021
Breast cancer treatment leads to a high risk of cardiovascular disease. But in women who receive implants after mastectomy, cardiac testing may be associated with potential diagnostic pitfalls and inaccuracies.